BOEHRINGER INGELHEIM AIMS 50% PRODUCTION IN TURKEY

The Germany-based pharmaceutical company Boehringer Ingelheim plans to manufacture one out of every two boxes of human health products to be used in Turkey domestically within five years. This will be possible when localization projects are completed, according to Mohammed Al-Tawil, Middle East, Turkey and Africa (META) Regional Managing Director and Head of Human Pharma for Boehringer Ingelheim. “We’ll produce pharmaceuticals for diabetes, central nervous system, and cardiovascular diseases in Turkey as a result of our localization project, which is the biggest investment our firm has made since it began operating in the country,” said Al-Tawil. The firm is working on the localization project in collaboration with the pharmaceutical company Abdi Ibrahim. “We aim to invest EUR 15m in the short-term. We also have a long-term investment plan and plan for the amount to grow organically in line with future needs,” said Al-Tawil. With the localization investment, pharmaceuticals needed by 700,000 patients will be manufactured in the country in the next five years. Boehringer Ingelheim’s Turkey operation grew by 54.1% over the course of the pandemic. The firm, which will focus on Type 2 diabetes and Idiopathic pulmonary fibrosis (IDF), plans to offer innovative pharmaceuticals in Turkey.